Marathon Capital Management
ANIP icon

Marathon Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Marathon Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.22M Sell
71,810
-180
-0.3% -$13.9K 1.07% 31
2026
Q2 		$5.96M Sell
71,990
-600
-0.8% -$48.1K 1.21% 27
2026
Q1 		$5.58M Buy
72,590
+2,925
+4% +$228K 1.25% 26
2025
Q4 		$5.5M Sell
69,665
-40
-0.1% -$3.46K 1.18% 27
2025
Q3 		$6.38M Sell
69,705
-2,320
-3% -$189K 1.46% 22
2025
Q2 		$4.7M Buy
72,025
+2,830
+4% +$184K 1.2% 24
2025
Q1 		$4.63M Sell
69,195
-700
-1% -$41.8K 1.23% 26
2024
Q4 		$3.86M Sell
69,895
-150
-0.2% -$8.61K 0.97% 30
2024
Q3 		$4.18M Sell
70,045
-250
-0.4% -$15.3K 1.01% 27
2024
Q2 		$4.48M Sell
70,295
-875
-1% -$56.8K 1.14% 19
2024
Q1 		$4.92M Buy
71,170
+1,350
+2% +$81.5K 1.17% 25
2023
Q4 		$3.85M Sell
69,820
-1,850
-3% -$102K 0.97% 29
2023
Q3 		$4.16M Buy
71,670
+3,025
+4% +$175K 1.05% 28
2023
Q2 		$3.7M Sell
68,645
-16,245
-19% -$720K 0.91% 30
2023
Q1 		$3.37M Buy
84,890
+12,000
+16% +$506K 0.83% 32
2022
Q4 		$2.93M Hold
72,890
– – 0.81% 28
2022
Q3 		$2.34M Sell
72,890
-1,570
-2% -$53.7K 0.67% 35
2022
Q2 		$2.21M Sell
74,460
-550
-0.7% -$15.9K 0.71% 32
2022
Q1 		$2.11M Buy
75,010
+240
+0.3% +$8.95K 0.61% 41
2021
Q4 		$3.44M Buy
74,770
+575
+0.8% +$24.7K 0.81% 31
2021
Q3 		$2.44M Buy
+74,195
New +$2.31M 0.55% 37

Other funds holding ANIP

New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Oliver Luxxe Assets
Oliver Luxxe Assets Gladstone, New Jersey $638M AUM 30.27% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Mitsubishi UFJ Asset Management (UK)
Mitsubishi UFJ Asset Management (UK) London, United Kingdom $213M AUM 36.38% 1-Year Est. Return
Polaris Capital Management
Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return
Kendall Capital Management
Kendall Capital Management Rockville, Maryland $605M AUM 38.16% 1-Year Est. Return
Samalin Investment Counsel
Samalin Investment Counsel Chappaqua, New York $319M AUM 12.97% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

Marathon Capital Management's ANIP Position: Q3 2026 in Review

Marathon Capital Management reduced its ANI Pharmaceuticals (ANIP) stake by 0.25% in Q3 2026, selling an estimated $13.9K and leaving 71,810 shares worth $5.22M. The position accounts for 1.07% of the portfolio, ranked #31.

Marathon Capital Management first reported a position in ANIP in Q3 2021 and has held it in 21 quarters since. The position peaked at $6.38M in Q3 2025. 43 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

  • Marathon Capital Management held 71,810 shares of ANI Pharmaceuticals worth $5.22M as of Q3 2026.
  • Marathon Capital Management sold 180 ANI Pharmaceuticals shares in Q3 2026, an estimated $13.9K.
  • ANI Pharmaceuticals made up 1.07% of Marathon Capital Management's portfolio in Q3 2026, its #31 holding.
  • Marathon Capital Management first reported a position in ANI Pharmaceuticals in Q3 2021 and has held it in 21 quarters since.
  • Marathon Capital Management's ANI Pharmaceuticals position peaked at $6.38M in Q3 2025.
  • 43 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on Marathon Capital Management's 13F filing for Q3 2026, filed 23 Oct 2026.